

10 Apr 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: time runs out to scale the next patent cliff; Novartis searches for new blockbuster; Boehringer Ingelheim's R&D spending pays off; Shanghai eyes mRNA vaccines as COVID cases rise; and the global pharma R&D pipeline hits new heights.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 8 April 2022, including: time runs out to scale the next patent cliff; [*Novartis AG*](#) searches for a new blockbuster; [*Boehringer Ingelheim GmbH*](#)'s R&D spending pays off; Shanghai eyes mRNA vaccines as COVID cases rise; and the global pharma R&D pipeline hits new heights.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall*](#)" - Scrip, 4 Apr, 2022.)

(Also see "[*Can Novartis Break Back Into The US Top Five? It Is Going To Need Bigger Blockbusters*](#)" - Scrip, 6 Apr, 2022.)

(Also see "[*Late-Stage Pipeline Blooming At Boehringer As R&D Spend Soars*](#)" - Scrip, 5 Apr, 2022.)

(Also see "[*Facing COVID Surge, China Revises Course To Support Imported mRNA Vaccines*](#)" - Scrip, 31 Mar, 2022.)

(Also see "[*COVID-19 Factor Wanes But Pharma's R&D Pipeline Hits Record Heights*](#)" - Scrip, 31 Mar, 2022.)

[*Click here to explore this interactive content online*](#) ✨